Anthem Biosciences shareholders approved all eight resolutions at its 20th Annual General Meeting held on July 22, 2026, including the adoption of audited financial statements for FY26 and the declaration of a dividend. The meeting, conducted via video conferencing, saw a robust participation rate of 95.59% of outstanding shares polled across key ordinary resolutions, reflecting strong engagement from both promoter and public stakeholders. While promoter support was unanimous across all agenda items, certain public institutional investors registered dissent on specific governance and related-party matters.

The scrutinizer report, submitted by BMP & Co. LLP under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirmed that all resolutions were passed with the requisite majority. The record date for voting was July 17, 2026, with 173,991 shareholders eligible to vote. Remote e-voting commenced on July 19, 2026, and concluded on July 21, 2026, followed by instant polling during the virtual meeting. Ms. Lakshmi M and Ms. Jayashree Sharma acted as independent witnesses for the unblocking of votes on July 22, 2026.

Voting Outcomes by Resolution

Shareholders overwhelmingly supported the adoption of the audited financial statements for the year ended March 31, 2026, and the reports of the Board of Directors and statutory auditors. This ordinary resolution received 100% support from promoters and nearly 100% from public non-institutional investors. The dividend declaration also secured near-unanimous approval, with only 74 votes cast against it out of over 538 million votes polled.

The re-appointment of Mr. K Ravindra Chandrappa (DIN: 01580534), who retires by rotation, was approved with 99.95% support. However, public institutional investors voted against this resolution at a rate of 0.26%, while promoter group support remained at 100%. Similarly, the appointment of M/S. S.R. Batliboi & Associates LLP as statutory auditors saw 99.99% overall support, with minimal dissent from public institutions.

Governance and Related-Party Approvals

A special resolution to approve the continuation of Mr. Ravikant Uppal (DIN: 00025970) as a non-executive independent director upon attaining the age of 75 years was passed with 98.99% support. Notably, public institutional investors voted against this resolution at a rate of 5.87%, indicating some scrutiny regarding tenure limits for independent directors.

The approval of commission payable to independent directors faced the highest level of dissent among all resolutions. While promoters voted unanimously in favor, public institutional investors opposed the resolution by 28.16%, resulting in an overall support rate of 95.19%. This suggests significant debate among large investors regarding director remuneration structures.

The increase in payment of remuneration to related parties holding an office or place of profit was approved with 99.05% support. Promoters abstained from voting on this resolution, leaving the decision entirely to public shareholders. Public institutions showed minor dissent at 1.40%, while non-institutional public shareholders supported the measure almost unanimously.

Strategic Partnership Approval

The final resolution concerned the Upside Sharing Arrangement with Viridity Tone LLP. This ordinary resolution received 85.27% overall support but faced substantial opposition from public institutional investors, who voted against it at a rate of 21.67%. Promoters again abstained from voting on this matter. The arrangement likely involves performance-linked incentives or equity-based rewards, which may have raised concerns among some institutional holders regarding dilution or payout structures.

Mr. Ajay Bhardwaj, Chairperson, Managing Director, and Chief Executive Officer, chaired the meeting. Ms. Divya Prasad, Company Secretary and Compliance Officer, oversaw the proceedings, while Mr. Pramod S M of BMP & Co. LLP served as the scrutinizer. The complete voting results and scrutinizer report are available on the company’s website at https://anthembio.com/ .

Anthem Biosciences has expressed confidence in its ability to regain a mid-teens growth rate, signaling a positive outlook for the company's business performance. The company's statement underscores its belief in the strength of its underlying business fundamentals and its capacity to return to stronger growth levels.

Growth Outlook

Anthem Biosciences indicated that it is focused on recapturing its mid-teens growth trajectory. The company's expressed confidence points to its assessment of prevailing business conditions and its strategic positioning within the biosciences sector.

Key Highlights

• Anthem Biosciences has publicly expressed confidence in returning to a mid-teens growth rate.
• The statement reflects the company's assessment of its business outlook.
• No specific financial figures, timelines, or quarterly data were provided in the available source material.